Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heavy Uterine Bleeding
Conditions
Heavy Uterine Bleeding, Uterine Fibroids
Trial Timeline
Apr 8, 2013 → Dec 1, 2015
NCT ID
NCT01817530About Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placebo
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placebo is a phase 2 stage product being developed by AbbVie for Heavy Uterine Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT01817530. Target conditions include Heavy Uterine Bleeding, Uterine Fibroids.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01817530 | Phase 2 | Completed |
Competing Products
3 competing products in Heavy Uterine Bleeding
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + Progesterone | AbbVie | Phase 2 | 52 |
| Elagolix + Estradiol /norethindrone acetate (E2/NETA) | AbbVie | Phase 3 | 77 |
| Vilaprisan (BAY1002670) | Bayer | Phase 3 | 74 |